Replimune's $150 million offering formalized in prospectus supplement filed with SEC

Replimune Group, Inc. filed a prospectus supplement on August 10, 2026 detailing the underwritten offering priced the same day. The company is offering 9,701,490 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants covering 2,736,340 additional shares.¹ The offering price is $12.0600 per share and $12.0599 per pre-funded warrant, with total gross proceeds of $149,999,956.¹

Each pre-funded warrant's purchase price equals the common stock offering price minus $0.0001, which serves as the warrant's exercise price.¹ Warrant holders cannot exercise if doing so, together with affiliates, would push beneficial ownership above 9.99% of outstanding shares, though holders may adjust that cap with 61 days' notice.² Delivery of the securities is expected on or about August 11, 2026.¹ Leerink Partners, J.P. Morgan, and Cantor are serving as bookrunning managers.¹

Net proceeds are estimated at approximately $140.5 million after underwriting discounts, commissions, and offering expenses.¹ Replimune said it plans to use the proceeds, combined with existing cash and potential borrowings under its Hercules Loan Agreement, to fund the commercial launch of TUDRIQEV, continue RPx platform development including skin cancer indication expansion, and broaden the RP2 clinical program.¹

The filing also lays out the path to TUDRIQEV's approval. After receiving two Complete Response Letters on its BLA, the most recent in April 2026, Replimune's application went before the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee on July 30, 2026, which voted 10 to 3 that the efficacy results from the IGNYTE study were evaluable and clinically meaningful.¹ Following that meeting, the FDA granted accelerated approval on August 6, 2026 for TUDRIQEV in combination with nivolumab in adults with unresectable advanced cutaneous melanoma who progressed on anti-PD-1 therapy, based on objective response rate and duration of response, with continued approval contingent on verification of clinical benefit in confirmatory trials including IGNYTE-3.¹